Design Therapeutics, Inc.
HealthcareNASDAQ:DSGN · NASDAQ Global Select
+$0.44 today
Vol 0.46M · Avg 0.73M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$69.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $622.0K +4.4% | $596.0K +11.0% | $537.0K +15.2% | $466.0K | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$622.0K -4.4% | -$596.0K -11.0% | -$537.0K -15.2% | -$466.0K | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $59.1M +33.3% | $44.4M -22.3% | $57.1M +17.4% | $48.6M +96.2% | $24.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.3M +12.8% | $18.0M -14.6% | $21.1M +11.3% | $19.0M +71.7% | $11.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $78.8M +27.6% | $61.8M -20.4% | $77.7M +15.7% | $67.1M +87.3% | $35.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $622.0K +4.4% | $596.0K +11.0% | $537.0K +15.2% | $466.0K +261.2% | $129.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$69.2M -41.2% | -$49.0M +26.1% | -$66.3M -5.5% | -$62.8M -77.5% | -$35.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$79.5M -27.4% | -$62.4M +20.2% | -$78.2M -15.7% | -$67.6M -88.6% | -$35.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.7M -24.4% | $12.8M | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.7M -24.4% | $12.8M +13.0% | $11.3M +164.4% | $4.3M +1337.9% | $298.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$69.8M -40.7% | -$49.6M +25.8% | -$66.9M -5.6% | -$63.3M -78.2% | -$35.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$69.8M -40.7% | -$49.6M +25.8% | -$66.9M -5.6% | -$63.3M -78.2% | -$35.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -38.6% | -$1 +26.1% | -$1 -4.4% | -$1 -48.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -38.6% | -$1 +26.1% | -$1 -4.4% | -$1 -48.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.3M +1.3% | $56.6M +1.1% | $56.0M +0.5% | $55.7M +21.3% | $45.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.3M +1.3% | $56.6M +1.1% | $56.0M +0.5% | $55.7M +21.3% | $45.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
I-Mab
IMAB
$235.66M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DSGN generate?
Design Therapeutics, Inc. (DSGN) reported $0.00 of revenue in fiscal 2025.
Is DSGN profitable?
Design Therapeutics, Inc. (DSGN) reported -$69,792,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.